Heba Omar

Citation:

Darweesh, S. K., K. Elsaeed, H. Omar, M. E. Raziky, W. elakel, M. E. Serafy, S. Ismail, A. A. Gomaa, M. Mehrez, M. Elkassas, et al., "High SVR rate following retreatment of non-sustained virological responders to sofosbuvir based anti-HCV therapies regardless RAS testing: A real-life multicenter study.", Expert review of gastroenterology & hepatology, 2019.

Abstract:

: we aimed at evaluating efficacy and safety of sofosbuvir/daclatasvir/ribavirin (SOF/DCV/RBV) in treating non-sustained virological responders (non-SVR12) to prior sofosbuvir-based therapy, in the setting of absence of RAS testing in mass treatment, and to determine the optimal timing to start re-treatment. : Real-life prospective observational study including 1,014 non-SVR12 who failed prior treatment with 24-weeks SOF-RBV (n=679, 67%) or 12-weeks SOF- RBV- PEG (n=335, 33%). Patients were retreated with daily sofosbuvir, daclatasvir plus ribavirin for 12 (n=270) or 24 weeks (n=744). The primary efficacy endpoint was SVR12. Safety endpoint was regimen adverse events. : The mean age was 52±9 years (58.48% men). Cirrhosis was documented in 46.98 and 27.5% of SOF-RBV and SOF-RBV-PEG non-responders respectively. Overall, SVR12 was 90.6% [92.2% for 12 weeks therapy and 90.05% for 24 weeks therapy]. Mild adverse events occurred in 5.13% and 32 (3.1%) discontinued treatment; with eight (0.78%) on-treatment mortalities. Multivariate regression revealed that higher baseline FIB4 and shorter interval before starting re-treatment (<6 months) were the independent predictors of non-SVR12. : SOF/DCV/RBV is an effective and safe treatment option for non-responders to prior sofosbuvir-based therapy. Six months after end of initial therapy is an optimum interval before starting retreatment to achieve favorable SVR.